Sunitinib News and Research

RSS
Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
New study offers valuable information on ocular drug metabolism and pharmacokinetics

New study offers valuable information on ocular drug metabolism and pharmacokinetics

New combination immune therapy for cancer is effective and has fewer side effects, study finds

New combination immune therapy for cancer is effective and has fewer side effects, study finds

Immune checkpoint inhibitor therapy results in longer treatment-free survival for patients with advanced renal cell carcinoma

Immune checkpoint inhibitor therapy results in longer treatment-free survival for patients with advanced renal cell carcinoma

Targeted drug shows promising activity in kidney cancer patients with brain metastases

Targeted drug shows promising activity in kidney cancer patients with brain metastases

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

First-in-kind kidney cancer drug developed at UTSW receives FDA approval

First-in-kind kidney cancer drug developed at UTSW receives FDA approval

Targeted drug combined with immunotherapy prolongs survival in patients with advanced kidney cancer

Targeted drug combined with immunotherapy prolongs survival in patients with advanced kidney cancer

Potentially promising therapeutic combination for renal cell carcinoma uncovered

Potentially promising therapeutic combination for renal cell carcinoma uncovered

Trial shows new first-line treatment option for patients with metastatic kidney cancer

Trial shows new first-line treatment option for patients with metastatic kidney cancer

Experts use genomic analysis tools to create personalized treatment for kidney cancer patients

Experts use genomic analysis tools to create personalized treatment for kidney cancer patients

Apoptosis protein API-5 more markedly expressed in chemoresistant triple-negative breast cancer

Apoptosis protein API-5 more markedly expressed in chemoresistant triple-negative breast cancer

Clinical analysis reveals high expression of apoptosis protein in chemoresistant TNBC

Clinical analysis reveals high expression of apoptosis protein in chemoresistant TNBC

Epigenetic changes can lead to development of GISTs, other cancers

Epigenetic changes can lead to development of GISTs, other cancers

Drug combinations could become first-line treatment for metastatic kidney cancer

Drug combinations could become first-line treatment for metastatic kidney cancer

Physicians more likely to prescribe drugs of manufacturers who paid them money

Physicians more likely to prescribe drugs of manufacturers who paid them money

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma